Soligenix Secures $7.5 Million Financing to Extend Operations Through 2026

Soligenix Inc. has completed a $7.5 million public offering that significantly extends the company's financial stability through the end of 2026. The financing involved the sale of 5,555,560 shares of common stock and accompanying warrants at $1.35 per share, with participation from both existing and institutional healthcare investors. This capital infusion comes at a crucial time for the late-stage biopharmaceutical company as it advances multiple therapeutic candidates through development and regulatory processes.

The proceeds from this offering are designated to fund research and development activities, commercialization efforts, working capital requirements, and general corporate purposes. A notable aspect of this financing arrangement includes the amendment of prior warrants to match the $1.35 exercise price, creating consistency across the company's financial instruments. The extended cash runway through 2026 provides Soligenix with substantial operational stability during a period when several of its key programs are approaching important milestones.

Soligenix's Specialized BioTherapeutics business segment is progressing toward potential commercialization of HyBryte (SGX301), a novel photodynamic therapy using safe visible light for treating cutaneous T-cell lymphoma. With successful completion of the second Phase 3 study, the company is preparing to seek regulatory approvals to support worldwide commercialization. Additional development programs in this segment include expanding synthetic hypericin into psoriasis treatment and advancing first-in-class innate defense regulator technology with dusquetide for inflammatory diseases including oral mucositis in head and neck cancer patients.

The company's Public Health Solutions business segment continues development of multiple vaccine candidates, including RiVax for ricin toxin protection and programs targeting filoviruses such as Marburg and Ebola. These vaccine development efforts incorporate Soligenix's proprietary heat stabilization platform technology known as ThermoVax. This business segment has received substantial support through government grant and contract funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority. Additional information about the company's developments is available at https://ibn.fm/SNGX.

The successful completion of this $7.5 million financing demonstrates continued investor confidence in Soligenix's strategic direction and pipeline potential. The extended financial runway through 2026 positions the company to advance its rare disease treatments through critical development stages while maintaining operational flexibility. This financing represents a significant step forward in Soligenix's mission to address unmet medical needs in rare disease treatment and public health solutions.